证券代码：000813 证券简称：德展健康 公告编号：2025-057 德展大健康股份有限公司关于持股5%以上股东所持公司股份第七次拍卖的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示： 1、本次拍卖是依据上海市第三中级人民法院（以下简称"上海市三中院"）裁定确认的《清算方案》执 行，本次公开拍卖股份为上海岳野股权投资管理合伙企业（有限合伙）（以下简称"上海岳野"）持有的 德展大健康股份有限公司（以下简称"公司"）97,154,647股无限售流通股（其所持公司股份总数为 137,154,647股，其中40,000,000股已被拍卖但尚未过户），占其所持公司股份的70.84%，占公司总股本 的比例为4.49%，占剔除公司回购专用账户股份数量后的公司总股本比例为4.63%1。 登录新浪财经APP 搜索【信披】查看更多考评等级 上述在网络拍卖中竞买成功的用户，必须依照标的物《竞买须知》《竞买公告》要求，按时交付标的物 网拍成交余款、办理相关手续。标的物最终成交以中国证券登记结算有限责任公司深圳分公司出具的过 户登记数据为准。 2、上海岳野不是公司 ...

证券代码：000813 证券简称：德展健康 公告编号：2025-057 德展大健康股份有限公司 关于持股 5%以上股东所持公司股份第七次拍卖的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次拍卖是依据上海市第三中级人民法院（以下简称"上海市三中院"） 裁定确认的《清算方案》执行，本次公开拍卖股份为上海岳野股权投资管理合 伙企业（有限合伙）（以下简称"上海岳野"）持有的德展大健康股份有限公 司（以下简称"公司"）97,154,647 股无限售流通股（其所持公司股份总数为 137,154,647 股，其中 40,000,000 股已被拍卖但尚未过户），占其所持公司股 份的 70.84%，占公司总股本的比例为 4.49%，占剔除公司回购专用账户股份数 量后的公司总股本比例为 4.63% 1。 2、上海岳野不是公司控股股东或实际控制人，其所持有的公司股份被拍卖 不会导致公司控制权发生变化，不会对公司的正常生产经营产生不利影响。 3、本次拍卖的竞买人为王梓旭、张寿春、陆岩等 8 名自然人。截至本公告 披露日，公司未知竞买人之间关系，以及是否 ...

7月23日，由新疆金融投资集团(以下简称：新疆金投)主办、德展健康（000813）承办的"新疆药物研发 创新及行业交流研讨会"在乌鲁木齐落下帷幕，汇聚政府部门、金融机构、教育行业、科技行业和医药 行业代表共同探讨新疆医药创新发展方向。中国工程院院士杨宝峰教授、韩德民教授受邀参加此次会 议。 资料显示，德展健康主要从事心脑血管药物的研发、生产和销售，是国产降血脂药龙头企业，曾连续八 年蝉联中国制药工业百强，主导起草制定了多项国家药品质量标准，曾荣获"国家科学技术进步二等 奖"。公司专注心脑血管、神经系统、抗肿瘤等重大医学领域攻关，药物研发管线涵盖化学药、生物药 及DNA核酸药一类创新药等。 目前，德展健康已建立完善的研发体系，建有四大专业医药研发平台、博士后工作站、院士工作站，并 与多所知名高校、科研院所达成技术与人才合作。正积极推进多个创新药项目，包括神经保护剂 WYY、抗血栓ZT、大麻二酚(CBD)相关药物等。 科研是医药研发企业永恒不变的核心竞争力，2024年底，德展健康公告与中国工程院杨宝峰院士签署了 《合作框架协议》，双方共同在心脑血管、肿瘤、代谢系统疾病、肺动脉高压、神经和精神类等多种领 域药品及保 ...

式回购公司股份 5,026,200 股，占公司目前总股本的 0.23%，具体内容详见公司 于 2024 年 9 月 4 日在巨潮资讯网（www.cninfo.com.cn）等指定信息披露媒体披 露的《关于首次回购公司股份的公告》（公告编号：2024-044）。 德展大健康股份有限公司（以下简称"公司"）分别于 2024 年 7 月 1 日及 东大会，审议并通过了《关于回购公司股份方案的议案》。基于对公司所属行业 前景的认可、对公司未来发展的信心及公司价值的判断，为进一步增强投资者信 心，稳定投资者预期，维护广大投资者的利益，公司计划自股东大会审议通过之 日起 12 个月内使用不低于人民币 2 亿元，不超过人民币 3 亿元的自有资金，通 过集中竞价交易方式以不超过人民币 3.59 元/股的价格回购股份。本次回购的股 份将全部用于注销减少公司注册资本。具体内容详见公司于 2024 年 7 月 19 日在 《证券时报》《证券日报》《上海证券报》《中国证券报》和巨潮资讯网 （www.cninfo.com.cn）披露的《回购报告书》（公告编号：2024-036）。2025 年 为"公司自有资金及金融机构借款"。 截至 ...

证券代码：000813 证券简称：德展健康 公告编号：2025-056 德展大健康股份有限公司 关于公司股份回购结果暨股份变动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司"）分别于 2024 年 7 月 1 日及 2024 年 7 月 18 日召开了第八届董事会第二十七次会议和 2024 年第一次临时股 东大会，审议并通过了《关于回购公司股份方案的议案》。基于对公司所属行业 前景的认可、对公司未来发展的信心及公司价值的判断，为进一步增强投资者信 心，稳定投资者预期，维护广大投资者的利益，公司计划自股东大会审议通过之 日起 12 个月内使用不低于人民币 2 亿元，不超过人民币 3 亿元的自有资金，通 过集中竞价交易方式以不超过人民币 3.59 元/股的价格回购股份。本次回购的股 份将全部用于注销减少公司注册资本。具体内容详见公司于 2024 年 7 月 19 日在 《证券时报》《证券日报》《上海证券报》《中国证券报》和巨潮资讯网 （www.cninfo.com.cn）披露的《回购报告书》（公告编号：2024-036 ...

Performance Forecast - The company expects a net loss for the period from January 1, 2025, to June 30, 2025, with an estimated loss of 25 million to 50 million yuan, compared to a profit of 10.15 million yuan in the same period last year [1] - The net profit attributable to shareholders is projected to decline by 346.24% to 592.48% compared to the previous year [1] - The basic earnings per share are expected to be a loss of 0.0117 to 0.0234 yuan per share, down from a profit of 0.0047 yuan per share last year [1] Reasons for Performance Change - The primary reason for the negative net profit is the impact of centralized procurement policies on the company's revenue, along with the fact that new business ventures are still in the development stage and have not yet contributed to profits [1]

Group 1 - The company held its 20th meeting of the 8th Supervisory Board on July 10, 2025, with 4 supervisors attending [1][2] - The meeting approved a proposal to amend the company's Articles of Association, changing the name of the shareholders' meeting to the shareholders' assembly and transferring the supervisory powers to the Board of Directors' Audit Committee [1][2] - The amendments will take effect upon approval by the shareholders' assembly, and the current Supervisory Board regulations will be abolished [1][2] Group 2 - The voting results for the proposal were unanimous, with 4 votes in favor, 0 against, and 0 abstentions [2] - The proposal will be submitted for further review at the shareholders' assembly [2] - The company has disclosed a comparison table of the amendments on its official information platform [2]

Meeting Information - The company will hold its first extraordinary general meeting of shareholders in 2025 on July 30, 2025, at 14:30 [1] - The meeting will include both on-site and online voting options, with specific time slots for each [1] Shareholder Rights - All ordinary shareholders registered by the close of trading on July 24, 2025, have the right to attend the meeting and can appoint proxies to vote on their behalf [2] - The meeting will also be attended by the company's directors, supervisors, senior management, and other required personnel [2] Agenda Items - The meeting will review several proposals, including amendments to the "Rules of Procedure for the Audit Committee of the Board" [3] - All proposals have been approved by the company's board and supervisory committee [3] Voting Procedures - Shareholders can vote through the Shenzhen Stock Exchange trading system and the internet voting system, with detailed procedures provided in the attachments [4][5] - Voting will be non-cumulative, meaning that if shareholders vote on both the total proposal and specific proposals, the first valid vote will be considered [5] Proxy Voting - A proxy authorization letter is required for representatives attending on behalf of shareholders, which must be submitted along with identification [4][8] - The authorization letter must specify the representative's name and the date of issuance [8]

Core Points - The company has revised its "Shareholders' Meeting Rules" to align with the latest legal regulations and its actual situation, changing the name from "Shareholders' General Meeting Rules" to "Shareholders' Meeting Rules" [1] - The revised rules clarify the responsibilities and powers of the shareholders' meeting, ensuring that it operates in accordance with the "Company Law" and other relevant regulations [1][2] - The rules now specify the procedures for convening, proposing, notifying, and holding shareholders' meetings, including the timelines for annual and extraordinary meetings [2][3] Group 1 - The company must hold an annual shareholders' meeting within six months after the end of the previous fiscal year, while extraordinary meetings can be called as needed [2][3] - If the company cannot convene a shareholders' meeting within the specified timeframe, it must report to the China Securities Regulatory Commission and the Shenzhen Stock Exchange [3] - The board of directors is required to convene the shareholders' meeting within the stipulated time and must provide written feedback on any proposals for extraordinary meetings from independent directors [3][4] Group 2 - Shareholders holding 10% or more of the company's shares can request the board to convene an extraordinary meeting, and the board must respond within 10 days [4][5] - If the board does not agree to convene the meeting, it must provide reasons and announce them [4][5] - The rules also allow the supervisory board or shareholders to convene meetings independently if the board fails to do so [5][6] Group 3 - The revised rules stipulate that shareholders can propose temporary proposals 10 days before the meeting, and the conveners must notify all shareholders of these proposals within 2 days [7][8] - All proposals must be fully disclosed in the meeting notifications to allow shareholders to make informed decisions [8][9] - The rules require that any election of directors or supervisors must provide detailed information about the candidates, including their backgrounds and any potential conflicts of interest [9][10] Group 4 - The company must hold the shareholders' meeting at its registered location or another location specified in its articles of association, ensuring that it is accessible to shareholders [10][11] - Shareholders can attend the meeting in person or through proxies, and each share carries one voting right [11][12] - The meeting must be presided over by a designated director or representative, and the minutes must accurately reflect the proceedings and decisions made [12][13] Group 5 - The rules emphasize that any resolutions passed at the shareholders' meeting must comply with legal and regulatory requirements, and any violations can be challenged in court [25][26] - The company is responsible for ensuring that the rights of minority investors are protected and that they can exercise their voting rights without obstruction [25][26] - The board of directors is tasked with executing the resolutions of the shareholders' meeting promptly to ensure the company's normal operations [26][27]

Core Viewpoint - Dezheng Health (000813) expects a net profit loss of 25 million to 50 million yuan in the first half of 2025, compared to a profit of 10.15 million yuan in the same period last year, representing a year-on-year decline of 346.24% to 592.48% [1] Financial Summary - The projected net profit loss for the first half of 2025 is between 25 million and 50 million yuan [1] - The profit for the same period last year was 10.15 million yuan [1] - The year-on-year decline in net profit is estimated to be between 346.24% and 592.48% [1]